| Identification | Back Directory | [Name]
L-Lysine, coMpd. with 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-1-Methyl-2-[(phosphonooxy)Methoxy]-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile and ethanol (1:1:1) (9CI) | [CAS]
914361-45-8 | [Synonyms]
Fosravuconazole L-lysine ethanolate
L-Lysine, coMpd. with 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-1-Methyl-2-[(phosphonooxy)Methoxy]-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile and ethanol (1:1:1) (9CI) | [Molecular Formula]
C31H40F2N7O8PS | [MDL Number]
MFCD33402307 | [MOL File]
914361-45-8.mol | [Molecular Weight]
739.73 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (67.59 mM; Need ultrasonic)| (insoluble) | [form ]
Solid | [color ]
White to yellow | [Water Solubility ]
Water : < 0.1 mg/mL (ultrasonic) |
| Hazard Information | Back Directory | [Uses]
Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a proagent of Ravuconazole, is an orally active broad spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used for candidiasis, onychomycosis and parasitemia research[1][2][3]. | [Biological Activity]
Fosravuconazole L-lysine ethanolate (BMS-379224 L-lysine ethanolate), a prodrug of Ravuconazole, is an orally active broad-spectrum antifungal agent. Fosravuconazole L-lysine ethanolate can be used in the study of candidiasis, onychomycosis and parasitic diseases. | [in vitro]
Fosravuconazole has potent in vitro antifungal activity against a wide range of fungal species, including Candida , Aspergillus , and Trichophyton species . | [in vivo]
Fosravuconazole (E-1224; 10-50 mg/kg; oral administration; daily; for 20 days) treatment suppresses the parasitemia and prevents death in mice infected with the T. cruzi Y strain. | Animal Model: | Swiss female mice (20-24 g) inoculated with trypomastigotes (Y strain). | | Dosage: | 10 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg , 50 mg/kg | | Administration: | Oral administration; daily; for 20 days | | Result: | Suppressed the parasitemia and prevented death. | | [References]
[1] Shinichi Watanabe, et al. Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. J Dermatol. 2018 Oct;45(10):1151-1159. DOI:10.1111/1346-8138.14607
[2] Katsura Hata, et al. Development of E1224 by leveraging a strategic partnership for the medicines creation against neglected tropical diseases. Parasitol Int. 2020 Dec 25;81:102278. DOI:10.1016/j.parint.2020.102278
[3] Lívia de Figueiredo Diniz, et al. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice. Antimicrob Agents Chemother. 2018 May 25;62(6):e00401-18. DOI:10.1128/AAC.00401-18 |
|
|